www.boehringer-ingelheim.com #2 Value through Innovation OUR COMPANY DIVERSITY & INCLUSION DRIVE INNOVATION MAKING MORE HEALTH HUMAN PHARMACEUTICALS SUSTAINABLE ECONOMIC & SCIENTIFIC ACTIVITY SUCCESSFUL BUSINESSES ANIMAL HEALTH (AS OF 01.01.2017) BIOPHARMACEUTICAL CONTRACT MANUFACTURING ECONOMIC SUCCESS (2016) RESEARCH & DEVELOPMENT Founded in 1885 in Ingelheim and family-owned to this day Biopharma 47% women* 33% GENERATION Y (1981-2000)* Respiratory diseases NET SALES RETURN ON NET SALES 35% female leaders* EUR 2,870 million Prescription Medicines expenditure in research & development in 2016 AMERICAS ≜ around 23.8% of Prescription Medicines net sales 2016 EUR 613 million TOTAL NET SALES 2016 EUR 1,460 million* TOTAL NET SALES *net sales (2016) prior to the integration of Merial EUR 6,542 million EUR 5,082 million EUR 4,226 million 18.1% EUR 15,850 million EUR 12,036 million TOTAL NET SALES PRESCRIPTION MEDICINES 2016 EUROPE ASIA, AUSTRALIA, AFRICA (AAA) Making More Health is a global initiative by Boehringer Ingelheim in cooperation with Ashoka, a non-governmental organ- isation. Its aim is to improve healthcare for people worldwide. Boehringer Ingelheim is a world-leading contract manufacturer of biopharmaceuticals. Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Human pharma of biopharmaceutical production sites in Europe, the USA and Asia Animal health FOCUS ON FOCUS ON Oncology GLOBAL PLAYER We have manufactured MORE THAN 25 BIOPHARMACEUTICALS for global markets ~ 50,000 employees worldwide at present MORE THAN 80 social entrepreneurs in over 30 countries received support since 2010 APPROX. 3 , 700 Boehringer Ingelheim employees worldwide are involved in the initiative Central nervous system + immunology Cardiometabolic diseases DIVERSITY IS ALSO ABOUT 54% PETS 5% EQUINE 17 % CATTLE 16% SWINE 8% POULTRY SHARE 59% COMPANION ANIMALS 41% LIVESTOCK Team composition Innovation / growth Balance DIVERSITY IS NOT ONLY ABOUT Compliance / ethics Minorities Individuals SOCIAL RESPONSIBILITY Focus on research therapeutic areas Scientific platforms Research Beyond Borders We operate 1 GLOBAL NETWORK We are a pioneer in biopharmaceuticals WITH OVER 35 YEARS of experience 3 PILLARS 17% BABY BOOMERS (1946-1964)* 50% GENERATION X (1965-1980)* *Boehringer Ingelheim worldwide, 2016